ModifiedAspirus ArisePolicy Utilization Review Policy 133

Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy

Prior authorization and coverage criteria for intravenous tocilizumab products (Actemra, Avtozma, Tofidence) for Aspirus Medicare Plans; defines indications, dosing, step therapy, and authorization durations for medical benefit coverage.

Policy Summary

PayerAspirus Arise

PolicyInflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy

Policy CodePolicy Utilization Review Policy 133

Change TypeCriteria updates, product additions, preferred biosimilar step added

Effective DateJan 1, 2021

Next Review Date

Key ActionObtain prior authorization and document indication-specific criteria, specialist involvement, prior therapy trials, and objective response or symptom improvement.

SourceLink

POLICY UPDATE CHANGES

Tyenne (preferred biosimilar) added; multiple tocilizumab IV products (Tofidence, Avtozma, others) and indications added/updated with revised age and dosing requirements.

Graft-versus-host disease and VEXAS syndrome added as approved indications.

Age requirements and dosing limits updated for several indications; polymyalgia rheumatica dosing changed to 8 mg/kg (max 800 mg).

Immunotherapy-related toxicity approvals expanded beyond inflammatory arthritis and added gastroenterologist/hepatologist/pulmonologist to accepted specialists.

3intravenous tocilizumab products named

Prior auth

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

authorization stance

Tyennestep therapy preferred product

12+distinct indications listed

3 itemsnot recommended scenarios

Coverage and Medical Necessity Criteria

inv-01: FDA-Approved Indications and Criteria

Coverage of Actemra, Avtozma and Tofidence is recommended for requests meeting both the preferred product step therapy requirements and indication requirements.

General approval preface: Prior authorization required; initial approval requires prescribing by or in consultation with a specialist; extended approvals allowed if criteria continue to be met.

See policy statement and step therapy sections

Cytokine Release Syndrome (CRS) - FDA Indication: Approve for 1 week if prescribed for a patient treated with CAR T-cell therapy.Dosing: Each dose: if <30 kg then up to 12 mg/kg to max 800 mg; if >=30 kg then up to 8 mg/kg to max 800 mg; approve up to four doses with >=8 hours between doses.

Children >=2 years indication described in overview; CAR T examples listed.

Giant Cell Arteritis - FDA Indication: Approve per initial or established therapy pathways.Initial: approve 6 months if ALL: patient >18 years, has tried or is currently taking a systemic corticosteroid (or corticosteroids contraindicated), and medication prescribed by or in consultation with a rheumatologist. Established: approve 1 year if established >=6 months AND (a) objective measure shows benefit OR (b) symptom improvement vs baseline. Dosing: up to 6 mg/kg to max 600 mg per dose every >=4 weeks.

Initial vs continuation pathways specified.

Polyarticular Juvenile Idiopathic Arthritis - FDA Indication: Approve for initial 6 months if ALL: patient >2 years, meets one of listed conditions (trial of one other systemic therapy OR starting concurrently with methotrexate/sulfasalazine/leflunomide OR absolute contraindication to those drugs OR aggressive disease), and prescribed by or in consultation with a rheumatologist. Established therapy: approve 1 year if established >=6 months and objective or symptomatic improvement.Dosing: if <30 kg: up to 10 mg/kg to max 800 mg per dose; if >=30 kg: up to 8 mg/kg to max 800 mg per dose; interval >=4 weeks between doses.

Examples of prior systemic therapies provided.

Rheumatoid Arthritis - FDA Indication: Initial therapy: approve 6 months if ALL: patient >18 years, tried one conventional synthetic DMARD for >=3 months (exception if prior biologic trial), and prescribed by or in consultation with a rheumatologist. Established therapy: approve 1 year if established >=6 months and objective or symptomatic improvement.Dosing: up to 8 mg/kg to max 800 mg per dose; interval >=4 weeks between doses.

Lists examples of conventional DMARDs and validated disease activity measures.

inv-02: Covered Indication Criteria (selected examples)

Covered when the specific indication's set of conditions are met (examples below reflect the policy's AND/OR logic):

Polyarticular or systemic juvenile idiopathic arthritis (examples): Initial therapy: patient meets age requirement (e.g., >2 years for SJIA), medication prescribed by or in consultation with a rheumatologist, and approve for 6 months; Continuation: established on therapy >=6 months AND patient has objective improvement OR symptom improvement; dosing limits: weight-based mg/kg with specified max and dosing interval.see dosing nodes

Examples of objective measures and symptoms are listed in policy

Rheumatoid arthritis: Initial therapy: patient >18 years, tried one conventional synthetic DMARD for >=3 months (unless prior biologic trial documented), prescribed by or in consultation with a rheumatologist — approve 6 months; Continuation: established on therapy >=6 months AND objective response OR symptom improvement — approve 1 year; dosing: up to 8 mg/kg to 800 mg max, >=4 weeks between doses.see dosing nodes

Exception: patients previously treated with biologic need not retry conventional DMARD.

inv-03: Summary of revised coverage criteria (history-driven)

Selected and annual revisions altered specific coverage criteria and prerequisites for indications; see items below.

Age requirements for initial approvals: For several indications initial approval requires minimum ages (e.g., Giant Cell Arteritis >=18, Rheumatoid Arthritis >=18, Polyarticular JIA >=2, Systemic JIA >=2, Castleman Disease >=18, Polymyalgia Rheumatica >=18)age

Applied to initial approvals as revised

Castleman disease initial therapy requirements: Requirements that patient is HIV and HHV-8 negative and use for relapsed/refractory or progressive disease were modified and later limited to unicentric vs multicentric disease; some unicentric relapsed/refractory requirement later removed.

See history for timeline of modifications

Immunotherapy-related toxicities: Approval requires that, according to the prescriber, the patient developed an immunotherapy-related toxicity while receiving a checkpoint inhibitor; accepted specialists expanded to include gastroenterologist, hepatologist, and pulmonologist; prior NSAID requirement removed.

This policy does not address the acute inpatient treatment of COVID-19. The policy statement explicitly notes that prior authorization recommendations and the listed criteria are intended for non-acute uses of intravenous tocilizumab products and that the acute treatment of COVID-19 in hospitalized patients is outside the scope of this document.

Although tocilizumab IV has an FDA‑recognized indication for certain hospitalized patients with COVID‑19 (hospitalized adults and pediatric patients ≥2 years receiving systemic corticosteroids and requiring supplemental oxygen or more intensive respiratory support), this policy does not target that acute COVID‑19 indication. The policy further clarifies that tocilizumab IV for COVID‑19 is generally only indicated in hospitalized adults meeting narrow criteria and that dosing for COVID‑19 is a single 8 mg/kg infusion (maximum 800 mg) with a possible second dose ≥8 hours later if clinically warranted.

Coverage is not recommended for use of tocilizumab IV in combination with another biologic or a targeted synthetic oral small molecule drug for an inflammatory condition. The policy states combination biologic/targeted‑synthetic regimens are generally not recommended due to higher potential adverse event rates and lack of controlled evidence supporting additive benefit.

The policy statement and history explicitly clarify that the acute treatment of COVID‑19 in hospitalized patients is not addressed by this policy. Historical edits removed some COVID‑19 language and updated the policy statement to reflect that acute inpatient COVID‑19 treatment is out of scope for these utilization recommendations.

Concurrent administration of tocilizumab IV with another biologic or with a targeted synthetic oral small molecule agent for inflammatory conditions is not recommended. The policy lists concurrent biologic/targeted synthetic combinations as a condition for which coverage is not recommended, and the history documents wording changes that retained this precaution.

Prior Authorization, Step Therapy, and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization is recommended for medical benefit coverage of tocilizumab intravenous products. Approval is recommended for requests that meet the indication-specific criteria and dosing in this policy. Initial approvals require the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Prior authorization recommended for medical benefit coverage (Actemra, Avtozma, Tofidence) — Tyenne is the preferred biosimilar
Requests for doses outside established dosing will be considered case-by-case by a clinician
Initial approval requires specialist prescriber or documented consultation

Prior Authorization

Indication-specific Prior Authorization Criteria

Coverage is recommended only when indication-specific prior authorization criteria are met. For FDA-approved and supported indications, the request must include documentation of indication-specific requirements (age limits, prior therapy trials, specialist involvement, and response documentation) as detailed in the policy.

Codes, Dosing Limits, and Age Limits

Biologics and oral therapies listed (appendix)mixed

Adalimumab SC Products	Humira ® , biosimilars
Certolizumab pegol SC injection	Cimzia ®
Etanercept SC Products	Enbrel ® , biosimilars
Infliximab IV Products	Remicade ® , biosimilars
Infliximab-dyyb SC injection	Zymfentra ®
Golimumab SC/IV	Simponi ® , Simponi Aria ®
Anakinra SC injection	(anakinra SC injection)
Mirikizumab IV/SC	Omvoh ®
Ustekinumab Products	Stelara ® IV/SC, biosimilars
Brodalumab SC injection	Siliq ®

1–10 of 25

1/3

Polymyalgia Rheumatica dosing maximum

Polymyalgia rheumatica — maximum single dose8 mg/kg per dose, maximum 800 mg per dose

Polymyalgia rheumatica — dosing intervalInterval between doses: at least 4 weeks

Polymyalgia rheumatica — approval duration examplesInitial approval commonly 6 months; continuation approvals may be 1 year if established and responding

Polymyalgia Rheumatica minimum age

Minimum age for PMR initial approval>= 18 years

Prescriber requirementMedication prescribed by or in consultation with a rheumatologist for initial approval

Key Definitions and Terms

Tocilizumab — brief definition and administration forms

DefinitionTocilizumab is an interleukin-6 (IL-6) receptor inhibitor administered by intravenous infusion (also available subcutaneously)

Forms availableIntravenous infusion (primary focus of this policy) and subcutaneous formulation

Clinical notesDosing modifications and interruptions may be used to manage laboratory abnormalities and adverse events; median doses for CRS in trials was one (range 1–4)

Cytokine Release Syndrome (CRS) — definition and relevance

DefinitionCytokine release syndrome (CRS) is a severe systemic inflammatory response often associated with CAR T-cell therapy and lymphocyte-engager therapies

Clinical relevance

Therapeutic Background and Scope

Tocilizumab is an interleukin‑6 (IL‑6) receptor inhibitor available for intravenous administration and indicated for multiple inflammatory conditions. While the agent has an FDA‑recognized COVID‑19 indication in certain hospitalized patients, this policy excludes the acute inpatient COVID‑19 treatment pathway from its coverage recommendations and instead focuses on inflammatory and immunologic indications (e.g., CRS from CAR T‑cell therapy, giant cell arteritis, juvenile idiopathic arthritis, rheumatoid arthritis, and others).

Policy Updates and Material Changes

2024-04-24addition

Tofidence IV was added to the policy with the same criteria as other tocilizumab intravenous products.

2024-10-10clarification

Policy statement updated to indicate the acute treatment of COVID-19 in hospitalized patients is not addressed in this policy.

2025-01-01step_therapy_change

UCare implemented a preferred biosimilar step effective 2025-01-01 requiring Tyenne as the preferred biosimilar prior to use of Actemra and Tofidence for patients new to therapy.

Policy Summary

PayerAspirus Arise

PolicyInflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy

Policy CodePolicy Utilization Review Policy 133

Change TypeCriteria updates, product additions, preferred biosimilar step added

Effective DateJan 1, 2021

Next Review Date

Key ActionObtain prior authorization and document indication-specific criteria, specialist involvement, prior therapy trials, and objective response or symptom improvement.

SourceLink

On This Page

Castleman disease: Initial approval: patient >18 years, if unicentric disease patient negative for HIV and HHV-8, medication prescribed by or in consultation with an oncologist or hematologist — approve 6 months; Continuation: established >=6 months AND objective response OR symptom improvement — approve 1 year; dosing: up to 8 mg/kg, interval >=2 weeks.see dosing nodes

Objective measures include CRP, ESR, fibrinogen, albumin, hemoglobin, BMI, lymphadenopathy.

Cytokine release syndrome from bispecific CD3 T-cell engager therapy: Approve for 1 week (adequate for four doses) for patients treated with or to be treated with a bispecific antibody; dosing weight-based up to specified max and up to four doses with >=8 hours between doses.four doses

Examples of bispecific antibodies are listed.

Graft-versus-host disease (acute): Initial therapy: patient >=18, acute GVHD, tried >=1 systemic medication for GVHD, prescribed by/consultation with transplant-affiliated physician/oncologist/hematologist — approve 1 month; Continuation for patients established >=1 month with response — approve 3 months; dosing up to 8 mg/kg per dose, interval >=2 weeks.established >=1 month for continuation

Systemic medication examples provided.

Immune checkpoint inhibitor-related toxicities: Initial therapy: patient >18, developed immunotherapy-related toxicity while on a checkpoint inhibitor, symptomatic despite trial of >=1 systemic corticosteroid, prescribed by/consultation with appropriate specialist — approve 6 months; Continuation: established >=6 months with objective or symptom improvement — approve 1 year; dosing up to 8 mg/kg to 800 mg max, interval >=4 weeks.trial of corticosteroid required

Examples of checkpoint inhibitors and accepted specialists listed.

Polymyalgia rheumatica: Initial therapy: patient >18, tried one systemic corticosteroid, prescribed by/consultation with a rheumatologist — approve 6 months; Continuation: established >=6 months with response — approve 1 year; dosing up to 8 mg/kg to 800 mg max, interval >=4 weeks.trial of corticosteroid

Objective measures include CRP/ESR and fever resolution.

Still's Disease, Adult Onset: Initial therapy: patient >18, prescribed by/consultation with a rheumatologist — approve 6 months; Continuation: established >=6 months with objective or symptom improvement — approve 1 year; dosing up to 8 mg/kg, interval >=2 weeks.age >18

SJIA referenced as same disease with different age of onset.

VEXAS syndrome: Initial therapy: patient >=18 with molecular genetic test showing pathogenic/likely pathogenic UBA1 variant, tried or currently taking systemic corticosteroid or corticosteroids contraindicated, prescribed by/consultation with specialist in autoinflammatory conditions — approve 6 months; Continuation: established >=6 months with response — approve 1 year; dosing up to 8 mg/kg, interval >=4 weeks.UBA1 pathogenic variant required

Examples of objective measures and symptoms listed.

Objective measures dependent on organ involvement and laboratory parameters may be used

Preferred biosimilar step for new-to-therapy patients: New-to-therapy patients may be required to try preferred biosimilar Tyenne before Actemra or Tofidence unless clinical need for non-preferred product is documented.

Effective 2025-01-01 per payer update

Conditions added as approval categories: Graft-versus-host disease and VEXAS syndrome were added as conditions of approval.

Dosing and interval revisions: Selected revisions updated dosing maxima and intervals for some indications (e.g., polymyalgia rheumatica dosing changed to 8 mg/kg max 800 mg; SJIA dosing interval changed from >=1 week to >=2 weeks).

See history entries for dates of changes

Follow the detailed indication criteria (e.g., rheumatoid arthritis, Castleman disease, VEXAS syndrome, immune checkpoint inhibitor toxicities) including age and diagnosis-specific requirements

Dosing and dosing intervals per indication must be met (e.g., up to 8 mg/kg with specified maximums and minimum dose intervals)

Documentation Required

Prescriber Specialty Requirement

Initial approval requires that the medication be prescribed by or in consultation with an appropriate specialist for the condition being treated. The policy lists examples of required specialties by indication.

Rheumatology required for rheumatoid arthritis and many inflammatory/autoimmune indications
Oncology/hematology required for Castleman disease and many malignancy-associated indications
Transplant center physician/affiliated specialist for transplant-related indications
Rheumatologist, hematologist, dermatologist, immunologist, or autoinflammatory specialist for VEXAS syndrome
Specialist involvement must be documented in chart notes or consultation notes at time of request

Documentation Required

Required Clinical Response Documentation

Requests must include objective clinical response documentation when required by the indication. Provide baseline and follow-up measures demonstrating benefit or symptom improvement.

Examples of objective measures: Physician Global Assessment (MD global), Parent/Patient Global Assessment (PGA), JDAS/cJDAS, JSpADA, standardized disease activity scores (CDAI, DAS28-ESR/CRP, RAPID-3, SDAI), and laboratory markers (CRP, ESR)
Symptom improvement documentation examples: decreased joint pain/tenderness, reduced morning stiffness or fatigue, improved function/ADLs, reduction in fever or rash, normalization or improvement of relevant labs
Chart notes must document baseline status prior to initiating therapy and subsequent improvement or benefit

Documentation Required

Diagnostic Test Requirement

Certain indications require diagnostic testing as part of initial approval. Provide required test results with the prior authorization request.

VEXAS syndrome: molecular genetic test demonstrating a pathogenic or likely pathogenic UBA1 gene variant is required
Castleman disease (unicentric): documentation of HIV and HHV8 negative status when applicable
Other indication-specific lab or diagnostic test requirements as listed in the detailed criteria must be provided

Step Therapy

Preferred Product Step Therapy Requirements

A preferred-product step therapy approach applies: Tyenne is the preferred biosimilar product and non-preferred biologics (Actemra, Avtozma, Tofidence) require meeting one of the specified exceptions A–E with chart-note documentation.

Preferred product: Tyenne. Non-preferred: Actemra, Avtozma, Tofidence
Step therapy exceptions (one of A–E must be met and documented): A) Patient is not a new start to the non-preferred product (used within prior 365 days); B) Documented allergy to a specific inactive ingredient in all preferred products; C) Documented adverse reaction to a specific inactive ingredient in all preferred products; D) Therapeutic success on the non-preferred product with prior failure of all preferred products during adequate trials (chart notes required); E) Patient diagnosis is included in FDA indications of the non-preferred product but not included for all preferred products
Patient or prescriber preference and facility/pharmacy stocking issues are not acceptable reasons to bypass step therapy
An adequate trial is generally considered ≥ 3 months unless otherwise specified or clinically justified

Step Therapy

Conventional DMARD Trial Requirement

For rheumatoid arthritis and other indications specifying conventional synthetic DMARD (csDMARD) trials, documentation of at least one adequate csDMARD trial is required unless an exception applies. Exceptions include prior adequate biologic trial documented or contraindication to csDMARDs as specified.

Examples of conventional DMARDs: methotrexate (oral or injectable), leflunomide, hydroxychloroquine, sulfasalazine
Rheumatoid arthritis initial therapy generally requires a trial of one csDMARD for at least 3 months, unless the patient has already had a 3-month trial of at least one biologic (in which case stepping back to a csDMARD is not required)
Chart notes must document duration and response to csDMARD trials or documentation of contraindication/intolerance

Associated documentationTrial of one systemic corticosteroid required for initial therapy per policy

Polyarticular Juvenile Idiopathic Arthritis minimum age

Minimum age for polyarticular JIA initial approval>= 2 years

Dosing general ruleIf <30 kg: up to 10 mg/kg to max 800 mg per dose; if >=30 kg: up to 8 mg/kg to max 800 mg per dose; interval >=4 weeks

Approval duration examplesInitial approval commonly 6 months; continuation approval 1 year if established >=6 months with improvement

Rheumatoid Arthritis minimum age

Minimum age for rheumatoid arthritis initial approval>= 18 years

Prior therapy requirementPatient must have tried one conventional synthetic DMARD for at least 3 months unless prior biologic trial documented

Dosing limitsApprove up to 8 mg/kg to a maximum of 800 mg per dose with at least 4 weeks between doses

Tocilizumab is indicated and recommended for treatment of CRS (recommended for all grades per guidelines)

Pediatric indicationCRS indication applies to patients >= 2 years of age per policy overview

Objective measure — examples of standardized clinical scores and lab markers

Examples of standardized clinical scoresPhysician Global Assessment (MD global), Patient/Parent Global Assessment (PGA/PDA), JADAS/cJADAS

Disease activity indicesCDAI, DAS28, RAPID-3, SDAI depending on indication

Laboratory markersC-reactive protein (CRP), erythrocyte sedimentation rate (ESR); normalization of liver function tests or blood counts may be used depending on organ involvement

SJIA / AOSD relationship

Relationship summarySystemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD) are considered the same disease differing by age of onset

Age-based routingFor patients >= 18 years the AOSD (adult-onset Still's disease) indication applies

Policy implicationInitial approval age thresholds were added/clarified in history (SJIA initial approvals require >=2 years; AOSD/Still's disease require >=18 years)

2025-06-11addition

Graft‑versus‑host disease was added as a condition of approval and immunotherapy‑related toxicities were expanded and revised (requirements added regarding onset while receiving a checkpoint inhibitor and accepted specialists expanded).

2025-08-13modification

Immunotherapy‑related toxicities expanded from inflammatory arthritis to broader checkpoint inhibitor‑related toxicities; specialist list expanded and prior NSAID requirement removed.

2025-09-24addition

Avtozma was added to the policy with the same criteria as other tocilizumab intravenous products.

2025-10-29revision

Castleman disease initial‑therapy requirements were modified to apply to patients with unicentric disease only and 'relapsed or refractory' language changed to 'relapsed/refractory or progressive' disease.

2025-12-03addition

VEXAS syndrome was added as a condition of approval and Castleman disease unicentric relapsed/refractory requirement was removed for initial therapy.

2026-05-08step_therapy_update

Step therapy criteria updated to require chart‑note documentation of clinical need for non‑preferred product over preferred products (Aspirus update dated 05/08/2025 shown in history entries leading to policy updates reflected in 2026 revisions).

2026-05-13dosing_and_interval_updatesLatest

Selected revisions adjusted dosing and intervals for some indications (e.g., SJIA dosing interval changed from ≥1 week to ≥2 weeks; polymyalgia rheumatica dosing changed from 6 mg/kg to 8 mg/kg with a higher max of 800 mg).

The document metadata and history show multiple selected revision timestamps after the recorded last revision date; selected revisions include dates in 2025 and 2026 (for example, 06/11/2025, 08/13/2025, 09/24/2025, 10/29/2025, 12/03/2025, 05/13/2026) as noted in the revision history.